Lipocine’s Partner Files New Drug Submission in Canada

Lipocine ( (LPCN) ) has shared an update.

On June 9, 2025, Lipocine announced that its licensing partner, Verity Pharma, filed a New Drug Submission for TLANDO® in Canada. TLANDO is the first oral testosterone replacement therapy approved by the FDA that does not require dose titration, representing a significant commercial opportunity in Canada, where over 700,000 prescriptions for testosterone replacement therapy are written annually. The filing marks an important step in expanding TLANDO’s market presence, potentially capturing a significant share of the Canadian market due to limited promotional activities for existing therapies.

The most recent analyst rating on (LPCN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.

Spark’s Take on LPCN Stock

According to Spark, TipRanks’ AI Analyst, LPCN is a Neutral.

Lipocine’s financial recovery is promising, with a strong balance sheet and reduced operational volatility. However, challenges remain in achieving consistent profitability and cash flow generation. Technical indicators show mixed signals, and the high P/E ratio suggests overvaluation, creating a cautious outlook.

To see Spark’s full report on LPCN stock, click here.

More about Lipocine

Lipocine Inc. is a biopharmaceutical company that utilizes its proprietary technology platform to enable effective oral delivery of therapeutics. The company focuses on developing drug candidates that offer differentiated, patient-friendly oral delivery options targeting large addressable markets with significant unmet medical needs. Lipocine’s portfolio includes treatments for conditions such as postpartum depression, epilepsy, essential tremor, obesity management, and liver cirrhosis, among others.

Average Trading Volume: 30,801

Technical Sentiment Signal: Sell

Current Market Cap: $16.96M

For a thorough assessment of LPCN stock, go to TipRanks’ Stock Analysis page.